PTC Therapeutics, Inc. (NASDAQ:PTCT) has been assigned an average rating of “Hold” from the ten ratings firms that are presently covering the firm, MarketBeat Ratings reports. Eight investment analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $14.63.

A number of equities analysts have recently weighed in on PTCT shares. Zacks Investment Research lowered PTC Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, May 11th. Barclays PLC reaffirmed an “equal weight” rating and issued a $13.00 price objective on shares of PTC Therapeutics in a research note on Wednesday, March 22nd. Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a $13.00 price objective on shares of PTC Therapeutics in a research note on Monday, March 6th. Credit Suisse Group reaffirmed a “positive” rating and issued a $25.00 price objective on shares of PTC Therapeutics in a research note on Monday, March 6th. They noted that the move was a valuation call. Finally, Citigroup Inc. set a $18.00 price objective on PTC Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, June 7th.

In other news, Director Dawn Svoronos bought 25,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 23rd. The shares were bought at an average cost of $13.49 per share, for a total transaction of $337,250.00. Following the completion of the transaction, the director now owns 25,000 shares of the company’s stock, valued at $337,250. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 7.80% of the stock is currently owned by insiders.

Large investors have recently bought and sold shares of the company. Tudor Investment Corp ET AL purchased a new stake in PTC Therapeutics during the first quarter worth approximately $410,000. Boxer Capital LLC purchased a new stake in PTC Therapeutics during the first quarter worth approximately $14,760,000. State Street Corp increased its stake in PTC Therapeutics by 219.1% in the first quarter. State Street Corp now owns 1,896,674 shares of the biopharmaceutical company’s stock worth $18,668,000 after buying an additional 1,302,278 shares in the last quarter. Camber Capital Management LLC purchased a new stake in PTC Therapeutics during the first quarter worth approximately $12,300,000. Finally, Schwab Charles Investment Management Inc. increased its stake in PTC Therapeutics by 5.8% in the first quarter. Schwab Charles Investment Management Inc. now owns 125,761 shares of the biopharmaceutical company’s stock worth $1,238,000 after buying an additional 6,840 shares in the last quarter. Institutional investors own 76.76% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright law. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/06/19/ptc-therapeutics-inc-ptct-receives-average-recommendation-of-hold-from-brokerages.html.

Shares of PTC Therapeutics (PTCT) traded up 1.24% during mid-day trading on Monday, reaching $17.20. The company had a trading volume of 1,118,099 shares. The stock’s market capitalization is $590.24 million. PTC Therapeutics has a one year low of $4.03 and a one year high of $17.63. The firm has a 50 day moving average of $13.74 and a 200-day moving average of $12.34.

PTC Therapeutics (NASDAQ:PTCT) last released its quarterly earnings results on Monday, May 8th. The biopharmaceutical company reported ($0.85) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.88) by $0.03. The business had revenue of $26.50 million during the quarter, compared to analyst estimates of $27.93 million. PTC Therapeutics had a negative return on equity of 98.77% and a negative net margin of 143.80%. PTC Therapeutics’s revenue for the quarter was up 40.2% on a year-over-year basis. During the same quarter in the previous year, the company posted ($1.22) earnings per share. Analysts forecast that PTC Therapeutics will post ($3.55) EPS for the current fiscal year.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid (RNA) biology. Its product pipeline includes Ataluren (Translarna), PTC596 and RG7916. Its product candidate, ataluren, is an orally administered small-molecule compound for the treatment of patients with genetic disorders due to a nonsense mutation.

Receive News & Ratings for PTC Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.